SESN News and Press, Sesen Bio Inc. From 11/07/22

Are Penny Stocks A Buy Under $1 Or Too Risky? The penny stock definition generally refers to stocks under $5. But if you’re an active trader, you know that isn’t the whole story. If you take out all other variables and leave the price as the only one, the cheaper the stock...

Sesen Bio press release ( NASDAQ: SESN ): Q3 GAAP EPS of $0.10. Revenue of $40M. Cash, cash equivalents and marketable securities were $184.9 million as of September 30, 2022, compared to cash and cash equivalents of $162.6 million as of December 31, 2021. Shares ...

Sesen Bio announced proposed merger with Carisma Therapeutics Combined company will focus on the advancement of Carisma’s development of engineered macrophages for the treatment of cancer and other serious disorders Transaction is expected to close in the next t...

Summary Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal. The main risk here is management pursuing a reverse-merger. Imara (IMRA) is a failed $60m ...

Cancer-focused biotech Sesen Bio, Inc. ( NASDAQ: SESN ) announced a merger agreement Wednesday with Carisma Therapeutics Inc., a closely held biopharma targeting immunotherapies. The all-stock transaction aims to form a combined company under the name Carisma Therapeutics ...

Sesen Bio ( NASDAQ: SESN ) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes e...

Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securiti...

Sesen Bio press release ( NASDAQ: SESN ): Q2 GAAP EPS of -$0.16 misses by $0.03 . Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of ...

Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 Sesen Bio (Nasdaq: SESN ) today reported op...

Nasdaq Listing Qualifications department notified Sesen Bio ( NASDAQ: SESN ) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its no...